Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Investors | Eli Lilly and CompanyEli Lilly’s weight loss drug Zepbound cuts heart failure risks in late-stage study CNBCEli Lilly’s weight loss drug Zepbound could cut heart failure risks, trial finds QuartzLilly says weight loss drug cuts heart failure risk by 38% in trial Reuters